Hanh L. Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanh L. Nguyen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Arun Nethi
Parkland Center for Clinical Innovation, Dallas, TX, USA
1 shared publicationBoryana Manz
Parkland Center for Clinical Innovation, Dallas, TX, USA
1 shared publication- Kristin Snackey Alvarez
Center of Innovation and Value at Parkland, Parkland Health Dallas Texas USA
1 shared publication Manjula Julka
Parkland Center for Clinical Innovation, Dallas, TX, USA
1 shared publicationVarun Sharma
Parkland Health and Hospital System, Dallas, TX, USA
1 shared publicationVenkatraghavan Sundaram
Parkland Center for Clinical Innovation, Dallas, TX, USA
1 shared publication
Latest Publications
- 25 November 2020
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 57 (1) , 52-60
Real-Time Risk Tool for Pharmacy Interventions
Adverse drug events (ADEs) result in excess hospitalizations. Thorough admission medication histories (AMHs) may prevent ADEs; however, the resources required oftentimes outweigh what is available in large hospital settings. Previous risk prediction models embedded into the Electronic Medical Record (EMR) have been used at hospitals to aid in targeting delivery of scarce resources. To determine if an AMH scoring tool used to allocate resources can decrease 30-day hospital readmissions. Propensity-matched cohort study, Medicine/Surgery patients in large academic safety-net hospital. Pharmacy-conducted AMHs identified by risk model versus standard of care AMH. A total of 30-day hospital readmissions and inpatient ADE prevention. The model screened 87 240 hospitalizations between June 2017 and June 2019 and 4027 patients per group were included. There were significantly less 30 day readmissions among high-risk identified patients that received a pharmacy-conducted AMH compared to controls (11% vs 15%; P = 0.004) and no significant difference in readmission rates for low-risk patients. While there was significantly higher documentation of major ADE prevention in the pharmacy-led AMH group versus control (1656 vs 12; P < 0.001), there was no difference in electronically-detected inpatient ADEs between groups. A risk tool embedded into the EMR can be used to identify patients whom pharmacy teams can easily target for AMHs. This study showed significant reductions in readmissions for patients identified as high-risk. However, the same benefit in readmissions was not seen in those identified at low-risk, which supports allocating resources to those that will benefit the most.
- 25 November 2020
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 57 (1) , 52-60
Real-Time Risk Tool for Pharmacy Interventions
Adverse drug events (ADEs) result in excess hospitalizations. Thorough admission medication histories (AMHs) may prevent ADEs; however, the resources required oftentimes outweigh what is available in large hospital settings. Previous risk prediction models embedded into the Electronic Medical Record (EMR) have been used at hospitals to aid in targeting delivery of scarce resources. To determine if an AMH scoring tool used to allocate resources can decrease 30-day hospital readmissions. Propensity-matched cohort study, Medicine/Surgery patients in large academic safety-net hospital. Pharmacy-conducted AMHs identified by risk model versus standard of care AMH. A total of 30-day hospital readmissions and inpatient ADE prevention. The model screened 87 240 hospitalizations between June 2017 and June 2019 and 4027 patients per group were included. There were significantly less 30 day readmissions among high-risk identified patients that received a pharmacy-conducted AMH compared to controls (11% vs 15%; P = 0.004) and no significant difference in readmission rates for low-risk patients. While there was significantly higher documentation of major ADE prevention in the pharmacy-led AMH group versus control (1656 vs 12; P < 0.001), there was no difference in electronically-detected inpatient ADEs between groups. A risk tool embedded into the EMR can be used to identify patients whom pharmacy teams can easily target for AMHs. This study showed significant reductions in readmissions for patients identified as high-risk. However, the same benefit in readmissions was not seen in those identified at low-risk, which supports allocating resources to those that will benefit the most.